<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533648</url>
  </required_header>
  <id_info>
    <org_study_id>2010.639</org_study_id>
    <nct_id>NCT02533648</nct_id>
  </id_info>
  <brief_title>Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients</brief_title>
  <acronym>DIAXO</acronym>
  <official_title>Involvement of Reactive Oxygen Species Produced by the Xanthine Oxidase in Mitochondrial Alterations in Skeletal Muscle of Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our recent data in mice have demonstrated a key role of xanthine oxidase in
      hyperglycemia-induced by Reactive oxygen species production, and a preventive role of
      allopurinol (inhibitor of xanthine oxidase) on the keeping of mitochondria number and
      structure, in skeletal muscle of diabetic mice. The investigators want to initiate a clinical
      trial in order to evaluate the efficacy of allopurinol on the improvement of mitochondrial
      alterations, oxidative capacities and insulin sensitivity, in skeletal muscle of type 2
      diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>muscle oxidative stress in diabetic patients</measure>
    <time_frame>At 3 months of treatment</time_frame>
    <description>muscular protein carbonylation level (unit: reactive carbonyl derivates, arbitrary unit) by Western blot (oxyblot kit from Chemicon) and pro et antioxidant genes expression (unit: mRNA levels normalized by housekeeping gene, arbitrary ratio) by real time polymerase chain reaction (RT-PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- plasmatic oxidative stress by dosing plasmaticmarkers:</measure>
    <time_frame>At 3 months of treatment</time_frame>
    <description>Dosing plasmatic malondialdéhyde, plasmatic H2O2, protein carbonylation of plasmatic protein and urinary isoprostans, and finally antioxidants (vitamins C and E, glutathione (unit: from µM to M)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alterations in mitochondrial structure of skeletal muscle with transmission electron microscopy</measure>
    <time_frame>At 3 months of treatment</time_frame>
    <description>Analysis of mitochondria area (in µm2) and density (in %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mitochondrial density by measuring the ratio mitochondrial Deoxyribonucleic acid (mtDNA)/nuclear DNA by real-time polymerase chain reaction (PCR) in skeletal muscle</measure>
    <time_frame>At 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mitochondrial function</measure>
    <time_frame>At 3 months of treatment</time_frame>
    <description>Expression of genes implicated in mitochondrial action (messenger Ribonucleic acid (mRNA) levels by Reverse transcription polymerase chain reaction (RT-PCR) and proteins levels by Western Blot)(unit: arbitrary ratio relative to housekeeping gene/protein).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantification of intramuscular lipids by histology (biopsy analysis)</measure>
    <time_frame>At 3 months of treatment</time_frame>
    <description>Staining Oil Red O evaluate the intramuscular lipid accumulation using the software ImageJ(unit: % of labelling by field).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensitivity to insulin using a hyperinsulinemic euglycemic clamp</measure>
    <time_frame>At 3 months of treatment</time_frame>
    <description>sensitivity to insulin will be expressed as the glucose infusion rate (GIR)/insulinemia ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>uricemia and xanthine oxidase activity in sera and muscles(unit: mg/l for uricemia and mU/ml for XO activity)</measure>
    <time_frame>At 3 months of treatment</time_frame>
    <description>Plasma concentrations of uric acid will be measured before and after treatment to assess patient compliance . The reduction of xanthine oxidase activity in serum and muscle protein lysates will be measured using the kit &quot; Amplex Red xanthine / xanthine oxidase assay kit&quot; from Molecular Probes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of the treatment measured by any adverse events during treatment and between each visit.</measure>
    <time_frame>during the 3 months of treatment</time_frame>
    <description>Any adverse events during treatment and between each visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allopurinol, experimental arms, type 2 diabetes subjects receive 2 capsules of allopurinol 150 mg daily for 3 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, type 2 diabetes subjects receive 2 capsules of lactose (placebo) daily for 3 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 capsules of allopurinol 150 mg daily for 3 month</intervention_name>
    <description>2 capsules of allopurinol 150 mg daily for 3 month</description>
    <arm_group_label>Allopurinol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2 capsules of lactose daily for 3 month</intervention_name>
    <description>2 capsules of lactose daily for 3 month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI from 25 to 40 kg/m²

          -  Type 2 diabetes known for over one year but less than 10 years, treated with Oral
             anti-diabetic drugs or a Glucagon-like peptide-1 (GLP1-analog)

          -  well controlled hypertension (untreated or currently treated) with a systolic blood
             pressure of 95 to 140 mmHg and diastolic blood pressure of 45 to 90 mmHg and heart
             frequency of 40 to 100 per minute

          -  Recent HbA1c &lt; 9 %

          -  Uricemia &gt; 300 µmol/l

          -  For women : Menopausal or contraception

          -  Renal function as defined by glomerular filtration rate (GFR) ≥ 80 mL/min/1.73 m2

        Exclusion Criteria:

          -  Tobacco ( more than 5 cigarettes)

          -  Excessive drinking

          -  Known pathology

          -  Hypersensitivity to allopurinol

          -  Treatment by anticoagulants, allopurinol, regular steroids or Nonsteroidal
             anti-inflammatory drug (NSAID), fibrate or insulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martine LAVILLE, Professor</last_name>
    <phone>+33 4.78 86 29 81</phone>
    <email>martine.laville@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Feugier</last_name>
    <phone>+33. 4 78 86 19 72</phone>
    <email>nathalie.feugier@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRNH Rhône Alpes</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine LAVILLE, Professor</last_name>
      <phone>+33. 4 78 86 29 81</phone>
      <email>martine.laville@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Nathalie FEUGIER</last_name>
      <phone>+33. 4 78 86 19 72</phone>
      <email>nathalie.feugier@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Martine LAVILLE, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus, oxidative stress</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>mitochondrial dysfunction</keyword>
  <keyword>skeletal muscle</keyword>
  <keyword>xanthine oxidase</keyword>
  <keyword>allopurinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

